First gene therapy to go on sale in Europe in 2013

November 5, 2012

Dutch biotech company uniQure said Monday it would start selling the first human gene therapy to be approved in the West by mid-2013 and predicted an explosion of similar therapies to come.

The European Commission approved Glybera on October 25, making the drug for treating the extremely rare disorder lipoprotein lipase deficiency (LPLD) the first to be approved for sale in Europe or North America.

"We believe that after Glybera's approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade," uniQure chief executive Joern Aldag said in a statement.

Gene therapy works by modifying a patient's DNA to combat a specific disease, and has been experimented with to treat everything from to depression and brain wasting diseases.

But the relatively unknown treatments have struggled to obtain regulatory approval in the West, although authorities in China approved a for treating as long ago as 2003.

Gene medicine burst on the medical scene in the late 1990s and is one of the most alluring areas of biotechnology, offering the theoretical promise of blocking or reversing inherited disease.

But this new frontier has also been hit by occasional setbacks, notably an unexpected or uncontrollable response from the immune system.

So far, successes have been few, limited to single-gene disorders—as opposed to complex multi-gene disorders that account for the commonest diseases.

Setbacks included the tragic death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer among two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.

Glybera treats LPLD, an inherited disease that affects around one or two people in a million, by preventing them from metabolising certain fat particles in the blood.

"First commercial sales of Glybera in Europe are expected in summer 2013," uniQure said, with the company also seeking approval for the drug in North America.

The company said it was developing a raft of other gene therapies to treat diseases including blood clotting disorder haemophilia B, metabolic disorder acute intermittent porphyria, central nervous system disorder Parkinson's and enzyme disorder Sanfilippo B.

Explore further: European regulator: Gene therapy treatment OK (Update)

Related Stories

European regulator: Gene therapy treatment OK (Update)

July 20, 2012
(AP) — The European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure ...

New advances in treating inherited retinal diseases highlighted in Human Gene Therapy

May 8, 2012
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in ...

Gene therapy is a 'disruptive science' ready for commercial development

January 24, 2012
The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology, which has demonstrated both its effectiveness and feasibility, ...

Study could help improve gene therapy for heart disease, cancer

October 12, 2011
A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.

To treat rare disease, NIH scientists repurpose FDA-approved drug

September 2, 2011
A new study reports that a drug already approved by the Food and Drug Administration for use in patients undergoing a bone marrow transplant may also have promise for treating people who have a rare immune deficiency known ...

Recommended for you

The 16 genetic markers that can cut a life story short

July 27, 2017
The answer to how long each of us will live is partly encoded in our genome. Researchers have identified 16 genetic markers associated with a decreased lifespan, including 14 new to science. This is the largest set of markers ...

A rogue gene is causing seizures in babies—here's how scientists wants to stop it

July 26, 2017
Two rare diseases caused by a malfunctioning gene that triggers seizures or involuntary movements in children as early as a few days old have left scientists searching for answers and better treatment options.

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.